European Community and US-FDA Approval of Recombinant Human Antithrombin Produced in Genetically Altered Goats

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 6, 2009, Pages 645-651

  Adiguzel, Cafer ^a   Iqbal, Omer ^a   Demir, Muzaffer ^a   Fareed, Jawed ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

antithrombin deficiency; genetically altered goats; hypercoagulability; recombinant antithrombin; thrombosis

Indexed keywords

ANTITHROMBIN III; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; DRUG APPROVAL; EUROPE; FOOD AND DRUG ADMINISTRATION; GENETICS; GOAT; HUMAN; LEGAL ASPECT; TRANSGENIC ANIMAL; UNITED STATES;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTITHROMBIN III; DRUG APPROVAL; EUROPE; GOATS; HUMANS; RECOMBINANT PROTEINS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 75549090256     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609339748     Document Type: Article

References (32)

1. Zhou Q., Kyazike J., Echelard Y., et al. Effect of genetic background on glycosylation heterogeneity in human antithrombin produced in the mammary gland of transgenic goats. J Biotechnol. 2005; 117(1):57-72.
2. Edmunds T., Van Patten SM, Pollock J., et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood. 1998; 91(12):4561-4571.
3. Hunt LT, Dayhoff MO. A surprising new protein super-family containing ovalbumin, antithrombin-III, and alpha 1-proteinase inhibitor. Biochem Biophys Res Commun. 1980; 95(2):864-871.
4. Kottke-Marchant K., Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med. 2002; 126(11):1326-1336.
5. Bucur SZ, Levy JH, Despotis GJ, Spiess BD, Hillyer CD. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion. 1998; 38(5): 481-498.
6. Choay J., Petitou M., Lormeau JC, Sinaÿ P., Casu B., Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high antifactor Xa activity. Biochem Biophys Res Commun. 1983; 116(2):492-499.
7. Hirsh J., Raschke R., Warkentin TE, Dalen JE, Deykin D., Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108(4 suppl):258S-275S.
8. Wiedermann CJ, Romisch J. The anti-inflammatory actions of antithrombin: a review. Acta Med Austriaca. 2002; 29(3):89-92.
9. O'Reilly MS, Pirie-Shepherd S., Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 1999; 285(5435): 1926-1928.
10. van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. Semin Hematol. 1997; 34(3):188-204.
11. Lane DA, Kunz G., Olds RJ, Thein SL Molecular genetics of antithrombin deficiency. Blood Rev. 1996; 10(2): 59-74.
12. Edeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965; 13: 516-530.
13. Sas G., Petö I., Bánhegyi D., Blaskó G., Domján G. Heterogeneity of the “classical” antithrombin III deficiency. Thromb Haemost. 1980; 43(2):133-136.
14. Lane DA, Olds RJ, Conard J., et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest. 1992; 90(6):2422-2433.
15. Lane DA, Olds RJ, Thein SL Antithrombin III: summary of first database update. Nucleic Acids Res. 1994; 22(17): 3556-3559.
16. Maclean PS, Tait RC Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs. 2007; 67(10):1429-1440.
17. Walker CPR, Royston D. Thrombin generation and its inhibition: a review of the scientific basis and mechanism of action of anticoagulant therapies. Br J Anaesth. 2002; 88(6):848-863.
18. Palmiter RD, Brinster RL, Hammer RE, et al. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature. 1982; 300(5893):611-615.
19. Rosen JM, Bayna E., Lee KF Analysis of milk protein gene expression in transgenic mice. MOI Biol Med. 1989; 6: 501-509.
20. Yom HC, Bremel RD. Genetic engineering of milk composition: modification of milk components in lactating transgenic animals. Am J Clin Nutr. 1993; 58(2 suppl): 299S-306S.
21. Maga EA, Murray JD Mammary gland expression of transgenes and the potential for altering the properties of milk. Biotechnology (NY). 1995; 13(13):1452-1457.
22. Clark AJ The mammary gland as bioreactor: expression, processing and production of recombinant proteins. J Mammary Gland Biol Neoplasia. 1998; 3(3):337-350.
23. van Berkel PHC, Welling MM, Geerts M., et al. Large scale production of recombinant human lactoferrin in the milk of transgenic cows. Nat Biotechnol. 2002; 20(5): 484-487.
24. Bick RL. Disseminated intravascular coagulation: a review of etiology, pathophysiology, diagnosis, and management: guidelines for care. Clin Appl Thromb Hemost. 2002; 8(1):1-31.
25. Recombinant human antithrombin III: rhATIII. Drugs R D. 2004; 5(2):110-112.
26. Ebert KM, DiTullio P., Barry CA, et al. Induction of human tissue plasminogen activator in the mammary gland of transgenic goats. BioTechnology. 1994; 12(7):699.
27. Avidan MS, Levy JH, Scholz J., et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology. 2005; 102(2):276-284.
28. Avidan MS, Levy JH, van Aken H., et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2005; 130(1):107-113.
29. Konkle BA, Bauer KA, Weinstein R., Greist A., Holmes HE, Bonfiglio J. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion. 2003; 43(3):390-394.
30. Tiede A., Tait RC, Shaffer DW, et al. Antithrombin alfa in hereditary antithrombin deficient patients: a phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost. 2008; 99(3):616-622.
31. Knight R., Stanley S., Wong M., Dolan G. Hemophilia therapy and blood-borne pathogen risk. Semin Thromb Hemost. 2006; 32(suppl 2):3-9.
32. Turner ML Prion reduction filters. Lancet. 2006; 368(9554):2190-2191.